Capital Research Global Investors Lowers Position in Establishment Labs Holdings Inc. $ESTA

Capital Research Global Investors cut its holdings in Establishment Labs Holdings Inc. (NASDAQ:ESTA) by 0.8% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 807,826 shares of the company’s stock after selling 6,665 shares during the quarter. Capital Research Global Investors’ holdings in Establishment Labs were worth $58,874,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in the business. Geode Capital Management LLC lifted its stake in Establishment Labs by 1.2% in the second quarter. Geode Capital Management LLC now owns 25,917 shares of the company’s stock worth $1,105,000 after acquiring an additional 299 shares during the period. Handelsbanken Fonder AB lifted its stake in Establishment Labs by 7.3% in the fourth quarter. Handelsbanken Fonder AB now owns 8,800 shares of the company’s stock worth $641,000 after acquiring an additional 600 shares during the period. Private Advisor Group LLC lifted its stake in Establishment Labs by 14.1% in the third quarter. Private Advisor Group LLC now owns 5,450 shares of the company’s stock worth $223,000 after acquiring an additional 675 shares during the period. Quarry LP purchased a new stake in Establishment Labs in the third quarter worth about $34,000. Finally, First Light Asset Management LLC lifted its stake in Establishment Labs by 0.3% in the third quarter. First Light Asset Management LLC now owns 418,358 shares of the company’s stock worth $17,148,000 after acquiring an additional 1,201 shares during the period. 72.91% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, Director Quiros Juan Jose Chacon sold 105,000 shares of the company’s stock in a transaction dated Wednesday, May 6th. The shares were sold at an average price of $75.42, for a total transaction of $7,919,100.00. Following the transaction, the director owned 927,504 shares in the company, valued at $69,952,351.68. This represents a 10.17% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders have sold a total of 330,000 shares of company stock worth $22,854,538 in the last 90 days. Corporate insiders own 9.99% of the company’s stock.

Establishment Labs Stock Up 6.7%

Shares of ESTA stock opened at $79.82 on Wednesday. Establishment Labs Holdings Inc. has a 1-year low of $33.35 and a 1-year high of $83.31. The stock’s fifty day moving average price is $67.28 and its 200 day moving average price is $68.87. The company has a debt-to-equity ratio of 16.82, a current ratio of 2.96 and a quick ratio of 1.91. The company has a market cap of $2.35 billion, a price-to-earnings ratio of -53.57 and a beta of 1.11.

Establishment Labs (NASDAQ:ESTA) last announced its earnings results on Thursday, May 7th. The company reported ($0.45) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.10). Establishment Labs had a negative return on equity of 218.77% and a negative net margin of 19.05%.The business had revenue of $59.88 million for the quarter, compared to analysts’ expectations of $57.40 million. During the same quarter last year, the firm earned ($0.70) earnings per share. The firm’s quarterly revenue was up 44.7% compared to the same quarter last year. On average, research analysts expect that Establishment Labs Holdings Inc. will post -1.07 earnings per share for the current fiscal year.

Analysts Set New Price Targets

ESTA has been the subject of a number of research reports. BTIG Research upped their price objective on shares of Establishment Labs from $88.00 to $90.00 and gave the stock a “buy” rating in a research note on Thursday, May 7th. Mizuho upped their price objective on shares of Establishment Labs from $90.00 to $100.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 25th. TD Cowen reaffirmed a “buy” rating on shares of Establishment Labs in a research note on Monday. Needham & Company LLC increased their price target on shares of Establishment Labs from $84.00 to $86.00 and gave the company a “buy” rating in a research report on Tuesday, February 24th. Finally, Canaccord Genuity Group increased their price target on shares of Establishment Labs from $85.00 to $90.00 and gave the company a “buy” rating in a research report on Thursday, February 26th. Seven research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $87.14.

Establishment Labs Profile

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.